Kailera Therapeutics (KLRA) officer Kathleen Tregoning files initial Form 3

Rhea-AI Filing Summary

Kailera Therapeutics, Inc. executive Kathleen Tregoning has filed an initial Form 3, which is a required ownership report for company insiders. The filing lists her as an officer of the company with no stock transactions or holdings reported in this submission.

Key Terms

Form 3, reporting insider, officer

3 terms

Form 3 regulatory

"Kathleen Tregoning has filed an initial Form 3, an ownership report"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reporting insider regulatory

"The Form 3 shows she has become a reporting insider of the company"

officer financial

"The Form 3 identifies Kathleen Tregoning as an officer of Kailera Therapeutics"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 07/08/2026 - 04:15 PM Accepted by SEC EDGAR 07/08/2026 - 04:15 PM Learn about SEC filing dates

FAQ

What does the Kailera Therapeutics (KLRA) Form 3 filing by Kathleen Tregoning mean?

The Form 3 shows that officer Kathleen Tregoning has become a reporting insider of Kailera Therapeutics. It is an initial ownership statement, and this filing reports no stock transactions or current holdings for her in this submission.

Did Kathleen Tregoning buy or sell any Kailera Therapeutics (KLRA) shares in this Form 3?

No, this Form 3 does not report any share purchases or sales by Kathleen Tregoning. The transaction summary shows zero buys, zero sells, and no derivative exercises, indicating it is purely an initial ownership registration.

What role does Kathleen Tregoning hold at Kailera Therapeutics (KLRA) in this Form 3?

The Form 3 identifies Kathleen Tregoning as an officer of Kailera Therapeutics, with her specific title referenced in the remarks section. This confirms she is considered an insider subject to ongoing ownership reporting requirements with the SEC.

Are there any derivative securities reported for Kathleen Tregoning in the KLRA Form 3?

No derivative securities are reported for Kathleen Tregoning in this Form 3. The derivative summary is empty and shows zero derivative transactions, indicating no options, warrants, or similar instruments are listed in this initial filing.

Does the KLRA Form 3 for Kathleen Tregoning indicate any gifts or tax withholdings of shares?

No, the transaction summary shows zero gifts and zero tax-withholding transactions for Kathleen Tregoning. This confirms the filing is an initial ownership statement only, without any concurrent share transfers or tax-related share dispositions.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Tregoning Kathleen

(Last) (First) (Middle)

C/O KAILERA THERAPEUTICS, INC.

180 THIRD AVENUE, 4TH FLOOR

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/29/2026

3. Issuer Name and Ticker or Trading Symbol
Kailera Therapeutics, Inc. [ KLRA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Chief Corporate Affairs Officer Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ John Mei, Attorney-in-fact	07/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)